Education
About Us
Working with TipRanks
Follow Us
LABORATORIO REIG JOFRE S.A. (ES:RJF)
BME:RJF
RJF Stock Chart & Stats
€2.68
€0.00(0.00%)
At close: 4:00 PM EST
€2.68
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€2.32 - €3.40
Previous CloseN/A
Volume1.57K
Average Volume (3M)44.99K
Market Cap
€192.74M
Enterprise Value€280.12M
Total Cash (Recent Filing)€10.84M
Total Debt (Recent Filing)€67.06M
Price to Earnings (P/E)41.7
Beta0.27
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.91%
Share Statistics
EPS (TTM)0.04
Shares Outstanding82,219,240
10 Day Avg. Volume48,066
30 Day Avg. Volume44,988
Financial Highlights & Ratios
PEG Ratio-0.79
Price to Book (P/B)0.96
Price to Sales (P/S)0.63
P/FCF Ratio-15.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.15
Revenue Forecast (FY)€349.90M
Bulls Say, Bears Say
Bulls Say
Diversified Revenue Model And PartnershipsA diversified commercial mix—direct sales to providers, pharmacies and hospitals plus partnerships and licensing—reduces single-market concentration. Strategic collaborations and licensing create durable channels for product distribution, technology access and potential royalty streams over the medium term.
Multi-year Revenue Expansion (2020–2024)Steady revenue expansion through 2024 reflects sustained product adoption and distribution reach prior to 2025. That multi-year growth indicates an established commercial footprint and market penetration that can provide a platform for recovery and mid-term revenue stability if operational issues are addressed.
Stable Historical EBITDA Margins (~10–11%)Relatively stable EBITDA margins before 2025 suggest underlying manufacturing scale and cost control in core operations. This structural operating efficiency implies the company can restore profitability if volumes and pricing normalize, supporting durable earnings power over several months.
Bears Say
2025 Sharp Revenue ContractionA ~20% revenue decline in 2025 materially reduces scale and breaks operating leverage, pressuring margins and net income. Such a large single-year drop may reflect structural demand loss, competitive displacement, or product issues that could take multiple quarters to correct and hamper long-term recovery.
Free Cash Flow Turned Sharply Negative In 2025A sharply negative FCF position drains liquidity and curtails the firm's ability to fund R&D, capex, or dividends internally. Combined with a history of FCF volatility, this increases reliance on external financing, raises refinancing risk, and limits flexibility to execute strategic initiatives over the medium term.
Rising Leverage In 2025Leverage increased meaningfully in 2025, reducing financial flexibility and amplifying earnings sensitivity to weak results. With margins compressed and cash flow impaired, higher debt levels raise interest and refinancing risks and constrain the company’s ability to invest in recovery or pursue opportunistic partnerships.
LABORATORIO REIG JOFRE News
RJF FAQ
What was LABORATORIO REIG JOFRE S.A.’s price range in the past 12 months?
LABORATORIO REIG JOFRE S.A. lowest stock price was €2.32 and its highest was €3.40 in the past 12 months.
What is LABORATORIO REIG JOFRE S.A.’s market cap?
LABORATORIO REIG JOFRE S.A.’s market cap is €192.74M.
When is LABORATORIO REIG JOFRE S.A.’s upcoming earnings report date?
LABORATORIO REIG JOFRE S.A.’s upcoming earnings report date is May 07, 2026 which is in 51 days.
How were LABORATORIO REIG JOFRE S.A.’s earnings last quarter?
LABORATORIO REIG JOFRE S.A. released its earnings results on Feb 27, 2026. The company reported €0.038 earnings per share for the quarter, beating the consensus estimate of N/A by €0.038.
Is LABORATORIO REIG JOFRE S.A. overvalued?
According to Wall Street analysts LABORATORIO REIG JOFRE S.A.’s price is currently Overvalued.
Does LABORATORIO REIG JOFRE S.A. pay dividends?
LABORATORIO REIG JOFRE S.A. pays a Annually dividend of €0.049 which represents an annual dividend yield of 1.91%. See more information on LABORATORIO REIG JOFRE S.A. dividends here
What is LABORATORIO REIG JOFRE S.A.’s EPS estimate?
LABORATORIO REIG JOFRE S.A.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does LABORATORIO REIG JOFRE S.A. have?
LABORATORIO REIG JOFRE S.A. has 82,219,240 shares outstanding.
What happened to LABORATORIO REIG JOFRE S.A.’s price movement after its last earnings report?
LABORATORIO REIG JOFRE S.A. reported an EPS of €0.038 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.515%.
Which hedge fund is a major shareholder of LABORATORIO REIG JOFRE S.A.?
Currently, no hedge funds are holding shares in ES:RJF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
LABORATORIO REIG JOFRE S.A.
Laboratorio Reig Jofre, S.A., a pharmaceutical company, researches, develops, manufactures, and markets pharmaceutical products and food supplements. The company offers prescription medicines, OTCs, medical devices, and cosmetics. Its products include pharmaceutical technologies products, such as antibiotics, and injectable and other products; specialty pharmacare products, which include skin, hair, and nail health, joint health and pain, women's health, respiratory/ENT, and pediatrics; and consumer healthcare products under the Forté Pharma brand. The company also provides CDMO and CMO services. It sells its products directly in 7 countries and through business partners in approximately 70 countries. The company was founded in 1929 and is based in Sant Joan Despí, Spain. Laboratorio Reig Jofre, S.A. is a subsidiary of Reig Jofre Investments SL.
Technical Analysis
Almirall
―
Faes Farma
―
Laboratorios Farmaceuticos Rovi
―
Oryzon Genomics SA
―
Atrys Health SA
―
Options Prices
Currently, No data available
---